SCHEDULE 13G: Rubric Capital Management Discloses 6.01% Stake in Integra Lifesciences

Rubric Capital Management LP and David Rosen have jointly disclosed a beneficial ownership of 6.01% in Integra Lifesciences Holdings Corporation, totaling 4,643,672 shares of common stock.

Summary

• Rubric Capital Management LP and David Rosen have filed a Schedule 13G, reporting their beneficial ownership in Integra Lifesciences Holdings Corporation.
• The reporting persons collectively beneficially own 4,643,672 shares of Integra Lifesciences' common stock.
• This ownership represents 6.01% of the outstanding common stock of Integra Lifesciences Holdings Corporation.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
• The percentage of class is based on 77,218,920 shares of Common Stock outstanding as of February 24, 2025, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. It is a neutral regulatory filing.

Risks

• The filing states that the shares were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11. This implies a potential for future proxy-related activities, such as nominating directors, which could lead to management or board changes.

Future Outlook

This document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the issuer's future outlook.

Industry Context

Integra Lifesciences Holdings Corporation operates in the medical technology and healthcare industry, providing products for neurosurgery, reconstructive surgery, and general surgery. The disclosure of a significant stake by an investment management firm like Rubric Capital Management indicates an institutional investor's interest in the company, which is a common occurrence in the publicly traded healthcare sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception and trading activity.
• Company Management: Awareness of a substantial shareholder, particularly one that explicitly reserves the right for proxy-related activities (e.g., nominations), could influence strategic decisions or investor relations.

Key Dates

Keywords

Integra Lifesciences Holdings Corporation, Rubric Capital Management LP, David Rosen, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Medical Technology, Healthcare, SEC Filing